Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 22, 2019
Pharmacy Choice - Pharmaceutical News - Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals - January 22, 2019

Pharmacy News Article

 1/6/19 - Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA Approvals

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

SOUTHBOROUGH, Mass.(BUSINESS WIRE) Veristat, a scientifically oriented clinical development and regulatory submission partner, announced today that it supported its biopharmaceutical clients on 12% of the US Food and Drug Administration (FDA) approvals granted in 2018, a record-setting year. In 2018, the FDA approved 59 drug and biologics therapeutic submissions for New Molecular Entities (NMEs)1. Veristat provided strategic planning as well as statistical analysis and medical writing for 12% of those approvals, including breakthrough oncology products as well as therapies for rare genetic-based disorders and infectious diseases.

Over the past 10 years, Veristat has prepared regulatory submissions for nearly 7% of all the NMEs approved by the FDA. In that time, our teams supported a total of 56 global regulatory submission projects. Of those, 40 have received approvals to date from the FDA, the European Medicines Agency (EMA), Health Canada and the Pharmaceuticals and Medical Devices Agency of Japan (PMDA) in a wide range of therapeutic areas, with many pending.

From our first FDA submission nearly 25 years ago, we have continued to provide our clients with collaborative strategic thinking and scientific insight into the regulatory submission planning and preparation required for submission to the FDA and other regulatory agencies, said John P. Balser, Ph.D., President and Co-Founder of Veristat. We are then able to implement the submission strategy through the efforts of our biometrics and regulatory medical writing divisions, providing a seamless submission process. But regardless of our successes, we never lose sight of our ultimate goal of helping our clients get therapies approved quickly to improve the lives of patients and their families.

The FDA approvals that our clients achieved in 2018 led to new treatment options for numerous cancers, hard-to-treat bacterial infections, and other rare diseases. Approvals from 2018 included TIBSOVO, the first and only targeted therapy for adult patients with relapsed/refractory Acute Myeloid Leukemia and an IDH1 mutation, and ONPATTRO? (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

Preparing regulatory submissions to achieve approval is a core strength for Veristat and our impact in 2018 and throughout the course of the past decade is impressive, stated Patrick Flanagan, Chief Executive Officer at Veristat. As we launch into 2019, our impact will improve with the further strategic growth of our clinical, biometric, medical writing and regulatory expertise that is specifically designed to plan and run more efficient clinical trials enabling the preparation of successful marketing applications.

Veristat delivers integrated submission preparation, full service clinical program expertise and the ability to achieve seemingly impossible deadlines. Our success lies in our ability to strategically navigate conceptually and operationally complex submissions, overcome data analysis challenges, and streamline the medical writing process with an integrated team focused on creativity, flexibility, and quality. Learn more at: https://www.veristat.com/services/medical-and-regulatory-affairs/regulatory-submissions.

About Veristat

Veristat is a scientifically oriented and impactful full-service clinical research organization (CRO) that is committed to partnering with pharmaceutical, biotechnology, and medical device firms to advance their therapies throughout the entire clinical development and regulatory submission process. Veristat helps clients solve the unique and complex challenges that arise when trying to accelerate therapies along the development pathway to successful regulatory approval, beginning with study design, protocol development, site selection and start-up through to clinical monitoring, data collection, analysis and reporting. Veristat provides experience-based strategic decision-making, the operational efficiencies to manage and monitor international trials, the biometrics expertise to collect, analyze and report clinical trial data to various regulatory agencies, and the therapeutic and medical proficiency to oversee the entire process. Ultimately, we guide our clients to market success so that their therapies become available to improve and save people's lives. For more information, visit https://www.veristat.com.

1 https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm592464.htm

Veristat:

Gillian Dellacioppa, Marketing Director

gillian.dellacioppa@veristat.com or +1 508-306-6336

Source: Veristat



Copyright Business Wire 2019

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jan 22: Medication Use During Pregnancy & Lactation
Last Chance
Jan 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Jan 24: COPD Update for Pharmacy Professionals
Jan 28: From Memory to Alzheimer’s - Supporting Memory With Lifestyle Medicine
Jan 29: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415